華仁藥業(300110.SZ):子公司猴痘病毒核酸檢測試劑盒(熒光PCR法)產品尚未產生訂單
格隆匯7月26日丨華仁藥業(300110.SZ)發佈股票交易異常波動公吿,公司注意到,據“央視新聞”報道,世界衞生組織2022年7月23日宣佈,在多個國家和地區發生的猴痘疫情構成“國際關注的突發公共衞生事件”。“國際關注的突發公共衞生事件”是世衞組織發佈的最高級別警報。
公司於2022年6月20日披露了《關於全資子公司檢測試劑產品獲得歐盟CE認證的公吿》,子公司青島華仁醫療用品有限公司的猴痘病毒核酸檢測試劑盒(熒光PCR法)和新型冠狀病毒(SARS-CoV-2)抗原檢測試劑盒等兩個產品獲得歐盟CE認證。子公司的猴痘病毒核酸檢測試劑盒(熒光PCR法)產品目前尚處於市場開發階段,尚未產生訂單,受出口政策、市場競爭及疫情發展變化等多種因素影響,目前尚無法預測其對公司未來業績的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.